N-(2,1,3-benzothiadiazol-4-yl)benzenesulfonamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(2,1,3-benzothiadiazol-4-yl)benzenesulfonamide
• 化学式: C₁₂H₉N₃O₂S₂
• 分子量: 291.4
• InChiKey: LJKBZEILYCVLOT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  109
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO 4,3-d]PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS
  申请人：MERCK PATENT GmbH

  公开号：EP1357915A2

  公开（公告）日：2003-11-05
• [EN] PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO[4,3-d]PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS<br/>[FR] PREPARATION PHARMACEUTIQUE COMPRENANT DES PYRAZOLO[4,3-D]PYRIMIDINES ET DES ANTAGONISTES DU RECEPTEUR DE L'ENDOTHELINE OU DES THIENOPYRIMIDINES ET DES ANTAGONSITES DU RECEPTEUR DE L'ENDOTHELINE
  申请人：MERCK PATENT GMBH

  公开号：WO2002062343A2

  公开（公告）日：2002-08-15

  Pharmaceutical preparation comprising at least one phosphodiesterase V inhibitor have, and/or physiologically acceptable salts and/or solvates thereof and at least one endothelin receptor antagonist for the preparation of a medicament for the treatment of angina, high blood pressure, high pulmonary pressure, congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), cor pulmonale, dextrocardiac insufficiency, atherosclerosis, conditions of reduced patency of the heart vessels, peripheral vascular diseases, strokes, bronchitis, allergic asthma, chronic asthma, allergic rhinitis, glaucoma, irritable bowel syndrome, tumours, renal insufficiency, liver cirrhosis, erectile dysfunction and for the treatment of female sexual disorders.